MilliporeSigma's expansion will help researchers produce at a scale that ensures these therapies reach more patients in need. Image courtesy of Merck.

MilliporeSigma previously invested in commercial viral and gene therapy manufacturing in 2016 with an initial Carlsbad facility. This site has 16 molecular viral bulk manufacturing cleanroom suites with single-use equipment and two fill/finish suites for gene therapy, viral vaccine, and immunotherapy products.

The new 140,000-sq-ft facility will support single-use viral and gene therapy production at the 1,000-liter scale. The expansion will add 11 suites for various manufacturing steps and nearly double the company's production capacity. The new site will help MilliporeSigma expand contract development and manufacturing services to the viral and gene therapy marketplace, the company said.

MilliporeSigma, Jenner Institute partner on COVID-19 vaccine
MilliporeSigma and the Jenner Institute have announced that they are preparing for large-scale manufacturing of the COVID-19 vaccine candidate ChAdOx1...

ReForm gets patents for therapeutic protein formulations
ReForm Biologics has received a U.S. patent for therapeutic protein formulations that reduce protein aggregation and stabilize proteins during storage.

MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second...

Serimmune, Merck reach drug discovery milestone
Serimmune has used its immune mapping technology on clinical and preclinical samples provided by Merck.